Loading…
Loading grant details…
| Funder | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES |
|---|---|
| Recipient Organization | University of California, San Francisco |
| Country | United States |
| Start Date | Jul 17, 2024 |
| End Date | May 31, 2026 |
| Duration | 683 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10951322 |
Project Summary/Abstract Quantification of drugs using the dried blood spots (DBS) remains uncommon due to the challenges of variability of DBS samples and correlation of DBS drug levels with plasma drug levels and clinical outcomes. In this proposal, we employ the volumetric absorptive microsampling (VAMS) technique to collect DBS samples and use ultra-performance liquid
chromatography tandem mass spectrometry to build a platform for quantitation of antimalarial drugs, including lumefantrine, amodiaquine and its metabolite desethylamodiaquine, and piperaquine, in the DBS samples. Then we will establish the correlation of DBS-plasma drug concentrations. Considering the unequal distribution of drugs in erythrocytes and plasma, high
protein binding, and variable hematocrit, comprehensive regression models will be tested to improve the accuracy of DBS-plasma conversion of drug concentrations. VAMS technique enables precise sampling of micro-volume samples regardless of hematocrit. such as Mitra™ DBS devices collecting 10 µL blood and HemaPEN™ DBS devices collecting 2.74 µL blood
samples with precision and accuracy
University of California, San Francisco
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant